Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Prime Medicine eyes 2026 regulatory filings as liver franchise gains momentum

Prime Medicine (NASDAQ:PRME) reported full-year 2025 financial results on Tuesday, signaling a strategic shift toward commercial-stage readiness as its "search-and-replace" gene editing platform achieves its first human clinical validations.

Leia mais: Prime Medicine eyes 2026 regulatory filings as liver franchise gains momentum